Skip to main content
NAVCO Pharmaceuticals logo

NAVCO Pharmaceuticals — Investor Relations & Filings

Ticker · NAV ISIN · CA63942R1091 LEI · 8945003WKDH61M8UB963 TSXV Manufacturing
Open in API
Filings indexed 199 across all filing types
Latest filing 2025-01-29 Audit Report / Informat…
Country CA Canada
Listing TSXV NAV

About NAVCO Pharmaceuticals

https://www.navcopharma.com/

NAVCO Pharmaceuticals is a biotechnology company specializing in the research, development, and commercialization of nanotechnology products and materials. The company utilizes proprietary Computerized Nano-meter Algorithms to create innovative solutions for anti-viral, anti-fungal, and anti-bacterial treatments. NAVCO focuses on developing supplemental and therapeutic consumer health and wellness products. A key offering is the BioActive™ line, which includes non-toxic, non-flammable, and alcohol-free hand cleansers, creams, and surface disinfectants designed to provide extended protection against germs and microorganisms. These nanotechnology products are marketed across various sectors, including medicine and textiles, providing next-generation protection solutions for multiple industries.

Recent filings

Filing Released Lang Actions
Audited annual financial statements – English.pdf
Audit Report / Information Classification · 95% confidence The document is a full set of audited financial statements for NAVCO Pharmaceuticals Inc. as at September 30, 2024, including an Independent Auditor’s Report, detailed notes, and financial statements. It is not an announcement or a presentation, but a standalone audit report. Thus, it fits the definition of an Audit Report/Information. FY 2024
2025-01-29 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that Navco Pharmaceuticals Inc. has received a Health Canada license for a new nanoparticle antimicrobial cream product. It focuses on product approval, market potential, and company information. There is no financial data, regulatory filing references, shareholder information, or meeting materials. The content is a corporate announcement about a product license, not a financial report, regulatory filing, or shareholder meeting document. Therefore, it best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2024-09-25 English
News release - English.pdf
Regulatory Filings
2024-09-17 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CFO of Navco Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. It references the interim filings but does not include them. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is 3012 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2024-09-10 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate by the CEO of Navco Pharmaceuticals Inc. It certifies the review and fair presentation of the interim financial report and interim MD&A for the period ended June 30, 2024. The document is primarily an officer certification letter and does not contain actual financial statements or substantive financial data. According to the Certification Rule, such certification documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself. The document length is 3013 characters, which is relatively short and consistent with a certification letter rather than a full interim report.
2024-09-10 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing that Navco Pharmaceuticals Inc. has received a Health Canada Natural Health Product licence for a new antimicrobial nanosilver skin shield product. It focuses on product approval and company information rather than financial data, regulatory filings, or shareholder information. There is no indication of financial results, management changes, voting results, or other regulatory filings. The content is promotional and informational about a product license approval, which does not fit into any of the specific financial or regulatory filing categories. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories. The document length is 4149 characters, which is relatively short and consistent with a press release rather than a detailed report.
2024-09-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.